A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BllB037 in Subjects with Prodromal or Mild Alzheimer's Disease

Conditions

Alzheimer´s Disease

What is the purpose of this trial?

This multi-center, double-blind, placebo-controlled study will evaluate the safety and tolerability of multiple doses of BIIB037 in subjects with prodromal or mild Alzheimer's disease. Subjects will be randomized to recieve either one of 3 doses of BIIB037 or placebo. The study period consists of screening, a 12-week treatment period, and an 18-week safety follow-up period.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Biogen Idec, Inc.
Dates:
10/25/2012
Last Updated:
Study HIC#:
1207010508